Novavax, Inc.

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instanceOf gptkb:biotechnology
gptkb:public_company
gptkbp:CEO gptkb:John_C._Jacobs
gptkbp:collaboratedWith gptkb:SK_Bioscience
gptkb:Takeda_Pharmaceutical_Company
gptkb:Serum_Institute_of_India
gptkbp:country gptkb:United_States
gptkbp:CUSIP 670002401
gptkbp:developedVaccineFor gptkb:COVID-19
influenza
gptkbp:focusesOn infectious diseases
vaccine development
gptkbp:founded 1987
gptkbp:foundedBy gptkb:John_Spears
Gale Smith
gptkbp:fundedBy gptkb:U.S._government
gptkb:Coalition_for_Epidemic_Preparedness_Innovations
gptkbp:headquartersLocation gptkb:Gaithersburg,_Maryland,_United_States
https://www.w3.org/2000/01/rdf-schema#label Novavax, Inc.
gptkbp:industry gptkb:biotechnology
gptkbp:ISIN US6700024010
gptkbp:keyPerson gptkb:John_C._Jacobs
Filip Dubovsky
Gale Smith
Gregory Glenn
Silvia Taylor
gptkbp:listedOn gptkb:NASDAQ
gptkbp:logo Novavax logo.svg
gptkbp:marketCap varies (publicly traded)
gptkbp:notableEvent COVID-19 pandemic vaccine development
gptkbp:notableProduct NanoFlu
Nuvaxovid (NVX-CoV2373)
ResVax
gptkbp:numberOfEmployees ~1500 (2023)
gptkbp:parentCompany independent
gptkbp:previousName gptkb:Novavax
gptkbp:product gptkb:Covovax
gptkb:Nuvaxovid
gptkbp:receivedEmergencyUseAuthorization gptkb:European_Union
gptkb:United_States
gptkb:World_Health_Organization
gptkbp:servesArea worldwide
gptkbp:stockExchange gptkb:NASDAQ
gptkbp:stockSymbol gptkb:NVAX
gptkbp:subsidiary Novavax AB
gptkbp:technology gptkb:Matrix-M_adjuvant
recombinant nanoparticle vaccine
gptkbp:tradedOn gptkb:NASDAQ:_NVAX
gptkbp:type public
gptkbp:website https://www.novavax.com/
gptkbp:bfsParent gptkb:NASDAQ:_NVAX
gptkb:NVAX
gptkbp:bfsLayer 7